feedback

Course Director

Bradley J. Monk, MD, FACS, FACOG
Bradley J. Monk, MD, FACS, FACOG

Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine - Phoenix
Creighton University School of Medicine at
St. Joseph's Hospital
Phoenix, Arizona‚Äč

Faculty

Robert Coleman
Robert Coleman, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Leslie M. Randall
Leslie M. Randall, MD, MAS

University of California, Irvine
Irvine, California

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2017-Jul-10
Expiration Date:2018-Jul-09
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free

Activity Description and Educational Objectives

Poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors represent an important new advance in the setting of ovarian cancer therapy. Multiple PARP inhibitors have gained indications for clinical use in different patient subsets and treatment settings, while others are in late-stage clinical development. As the ovarian cancer treatment landscape continues to advance, gynecologic and medical oncology professionals are challenged with adopting a more nuanced and complex approach to managing this disease. In this educational activity based on a recent live symposium, a panel of top experts in ovarian cancer presents the highlights of emerging science and clinical data on PARP inhibition and provides guidance on personalized disease management. An illustrative case scenario is presented to engage the audience in a stimulating discussion about how best to tailor therapy throughout the disease continuum and maximize the use of novel PARP inhibitor therapy to improve outcomes in advanced ovarian cancer. In addition, this unique activity incorporates the patient voice into the educational experience, pointing to the results of a patient survey at relevant points throughout the symposium; discussions focus on clinician–patient communications regarding patients’ perspectives, experiences, and needs, shared decision-making, and addressing practical issues that may arise during a patient’s therapeutic journey.

Upon completion of this activity, participants should be better able to:
  • Discuss the rationale for PARP inhibition and the potential clinical applications of and latest evidence on PARP inhibitors for the treatment of advanced ovarian cancer
  • Describe biomarker assays to identify ovarian cancer patient populations—such as those with BRCA-mutant, HRD-positive, or BRCA–wild type/high LOH tumors—that are likely to benefit from treatment with PARP inhibitors
  • Counsel ovarian cancer patients on the safe and effective clinical application of novel PARP inhibitors, including recommendations for enrollment into clinical trials
  • Provide appropriate disease- and treatment-related education and guidance to patients with ovarian cancer to enable them to meaningfully participate in planning and decisions related to their care

Target Audience

This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, surgical oncologists, and other clinicians involved in the management of ovarian cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 10, 2017 - July 09, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator
Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine - Phoenix
Creighton University School of Medicine at
St. Joseph's Hospital
Phoenix, Arizona

Bradley J. Monk, MD, FACS, FACOG, has a financial interest/relationship or affiliation in the form of:
Consultant for Advaxis; Amgen Inc.; AstraZeneca; Biodesix; Clovis Oncology, Inc.; Cue; Gradalis; F. Hoffmann-La Roche/Genentech, Inc.; ImmunoGen, Inc.; Insys Therapeutics, Inc.; Mateon Therapeutics; Merck & Co., Inc.; Perthera, Inc.; Pfizer Inc.; PPD, LP.; Precision Oncology; and TESARO, Inc.
Grant/Research Support from Amgen Inc.; Array BioPharma; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Morphotek Inc.; and TESARO, Inc.
Speakers Bureau participant with AstraZeneca; Clovis Oncology, Inc.; F. Hoffmann-La Roche/Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and TESARO, Inc.

Bradley J. Monk, MD, FACS, FACOG, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various PARP inhibitors alone or in combination regimens in various treatment/disease settings for ovarian cancer.

Faculty
Robert Coleman, MD
Professor, Department of Gynecologic Oncology and Reproductive Medicine
Vice Chair of Clinical Research
The University of Texas MD Anderson Cancer Center
Houston, Texas

Robert Coleman, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie; Debiopharm Group; Genmab; ImmunoGen, Inc.; Merck Sharp & Dohme Pharmaceuticals; Merrimack Pharmaceuticals, Inc.; Navigant Consulting, Inc.; Perthera, Inc.; Vaniam Group LLC; and Verastem Inc.
Grant/Research Support from Array BioPharma; AstraZeneca; Clovis Oncology, Inc.; EMD Serono, Inc.; Gradalis; Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc.
Speakers Bureau participant with Bio Ascend (CME); CancerNet (CME); F. Hoffmann-La Roche; and Onc Live.
Advisory Board for AstraZeneca; Bayer Healthcare, Inc.; Caris Life Sciences; Cerulean; Clovis Oncology, Inc.; F. Hoffmann-La Roche; GamaMabs; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Novocure; Pfizer Inc.; Precision Oncology; and TESARO, Inc.

Robert Coleman, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various PARP inhibitors alone or in combination regimens in various treatment/disease settings for ovarian cancer.

Leslie M. Randall, MD, MAS
Associate Professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
University of California, Irvine
Irvine, California

Leslie M. Randall, MD, MAS, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Clovis Oncology, Inc.; Mateon Therapeutics, Inc.; On Target Laboratories; and Pfizer Inc.
Grant/Research Support from Amgen Inc; Array BioPharma; Genentech, Inc.; Mateon Therapeutics, Inc.; On Target Laboratories; and Pfizer Inc.
Speakers Bureau participant with AstraZeneca.

Leslie M. Randall, MD, MAS, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various PARP inhibitors alone or in combination regimens in various treatment/disease settings for ovarian cancer.

CME Reviewer
Shaina Rozell, MD, MPH
Northwestern University
Chicago, Illinois

Shaina Rozell, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director
Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from Clovis Oncology, Inc. and TESARO, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.